Comparative Analysis of Antibody Titers against the Spike Protein of SARS-CoV-2 Variants in Infected Patient Cohorts and Diverse Vaccination Regimes.

Autor: Odainic A; Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany.; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection & Immunity, University of Melbourne, Melbourne, VIC 3010, Australia., Spitzer J; Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany., Szlapa JB; Institute of Experimental Immunology, University Hospital Bonn, 53127 Bonn, Germany., Schade S; Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany., Krämer TJ; Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany., Neuberger J; Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany., Bode C; Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, 53127 Bonn, Germany., Steinhagen F; Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, 53127 Bonn, Germany., Schmithausen RM; Institute for Hygiene and Public Health, University Hospital Bonn, 53127 Bonn, Germany., Wilbring G; Institute for Hygiene and Public Health, University Hospital Bonn, 53127 Bonn, Germany., Sib E; Institute for Hygiene and Public Health, University Hospital Bonn, 53127 Bonn, Germany., Mutters NT; Institute for Hygiene and Public Health, University Hospital Bonn, 53127 Bonn, Germany., Rabenschlag F; Medical Corps of the German Armed Forces, German Armed Forces Central Hospital, 56072 Koblenz, Germany., Kettel L; Medical Corps of the German Armed Forces, German Armed Forces Central Hospital, 56072 Koblenz, Germany., Woznitza M; Medical Corps of the German Armed Forces, German Armed Forces Central Hospital, 56072 Koblenz, Germany., van Bremen K; Department of Internal Medicine I, University Hospital Bonn, 53127 Bonn, Germany., Peers T; Clare Park Hospital, Farnham GU10 5XX, UK., Medinger G; Department of Paramedic Science, School of Health and Social Work, University of Hertfordshire, Hatfield AL10 9AB, UK., Kudaliyanage A; Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany., Kreutzenbeck M; Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany., Strube U; Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany., Johnson JM; Quanterix Corporation, Billerica, MA 01821, USA., Mattoon D; Quanterix Corporation, Billerica, MA 01821, USA., Ball AJ; Quanterix Corporation, Billerica, MA 01821, USA., Scory S; Meso Scale Diagnostics, Rockville, MD 20850, USA., McGuire R; Meso Scale Diagnostics, Rockville, MD 20850, USA., Putensen C; Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, 53127 Bonn, Germany., Abdullah Z; Institute of Experimental Immunology, University Hospital Bonn, 53127 Bonn, Germany., Latz C; Dardenne Eye Hospital, 53177 Bonn, Germany., Schmidt SV; Institute of Innate Immunity, University Hospital Bonn, 53127 Bonn, Germany.
Jazyk: angličtina
Zdroj: International journal of molecular sciences [Int J Mol Sci] 2022 Oct 13; Vol. 23 (20). Date of Electronic Publication: 2022 Oct 13.
DOI: 10.3390/ijms232012231
Abstrakt: The presence of neutralizing antibodies against SARS-CoV-2 correlates with protection against infection and severe COVID-19 disease courses. Understanding the dynamics of antibody development against the SARS-CoV-2 virus is important for recommendations on vaccination strategies and on control of the COVID-19 pandemic. This study investigates the dynamics and extent of α-Spike-Ab development by different vaccines manufactured by Johnson & Johnson, AstraZeneca, Pfizer-BioNTech and Moderna. On day 1 after vaccination, we observed a temporal low-grade inflammatory response. α-Spike-Ab titers were reduced after six months of vaccination with mRNA vaccines and increased 14 days after booster vaccinations to a maximum that exceeded titers from mild and critical COVID-19 and Long-COVID patients. Within the group of critical COVID-19 patients, we observed a trend for lower α-Spike-Ab titers in the group of patients who survived COVID-19. This trend accompanied higher numbers of pro-B cells, fewer mature B cells and a higher frequency of T follicular helper cells. Finally, we present data demonstrating that past infection with mild COVID-19 does not lead to long-term increased Ab titers and that even the group of previously infected SARS-CoV-2 patients benefit from a vaccination six months after the infection.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje